BioMarin Pharmaceutical Inc. (BMRN)
Nasdaq · Healthcare · Biotechnology
$57.54+0.63%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.1B
- P/E (trailing)
- 155.5
- Forward P/E
- 8.7
- 52-week range
- $49.26 – $70.98
- 52-week change
- +4.53%
- EPS (trailing)
- $0.37
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 26, 2026
Fiscal year to Dec 2025
- Revenue
- $3.2B (+12.87%)
- Net income
- $349M
- Operating margin
- 12.7%
- Diluted EPS
- $1.80
- Free cash flow
- $725M
From the company’s annual report on SEC EDGAR.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Headquarters: San Rafael, United States · 3,221 employees · biomarin.com